Medications

First biosimilar approved to treat multiple sclerosis

The U.S. Food and Drug Administration approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection, for the treatment of relapsing forms of multiple sclerosis, the agency announced Thursday.

Diseases, Conditions, Syndromes

FDA OKs second treatment for neuromyelitis optica spectrum disorder

(HealthDay)—Uplizna (inebilizumab-cdon) injection is now approved to treat neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody positive, the U.S. Food and Drug Administration ...

Oncology & Cancer

FDA approves first-line therapy for peripheral T-cell lymphoma

(HealthDay)—The U.S. Food and Drug Administration on Friday expanded approval for the use of Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with specific types of peripheral ...

Oncology & Cancer

Adcetris FDA approval expanded to include later-stage Hodgkin's

(HealthDay)—U.S. Food and Drug Administration approval of Adcetris (brentuximab vedotin) has been expanded to include adults with untreated stage III or IV classical Hodgkin's lymphoma, the agency said Tuesday in a news ...

Diseases, Conditions, Syndromes

Researchers shed light on pathway from virus to brain disease

Why people on immunosuppressant drugs for autoimmune conditions have a higher incidence of an often-fatal brain disease may be linked to a mutation in a common virus, according to researchers at Penn State College of Medicine.

page 1 from 3